TABLE 1.

Overview of the Studied Samples and Corresponding Applied Definitions and Technologies

Study Cohort	Subgroups	Serum	Mucosa (RNAseq*/microarray**)
Treatment-naïve newly diagnosed patients with IBD (within 6 months after diagnosis, naïve for biologics/immunosuppressives, no IBD-related surgery)	CD	41	16 colonic* 13 ileal*
	UC	17	11 colonic*
	Control patients without IBD	41	16 colonic* 15 ileal*
	Poor prognosis (need for biologic therapy within 2 years after diagnosis)	38	18 colonic*
	Good prognosis	13	9 colonic*
Anti-TNF cohort	Remission (complete absence of ulcerations at month 6 [CD] or a Mayo endoscopic subscore 0-1 at week 8/14 [UC]) No remission	91 95	13 colonic* 12 colonic*
Vedolizumab cohort	Remission (complete absence of ulcerations at month 6 [CD] or a Mayo endoscopic subscore 0-1 at week 14 [UC])	99	23 colonic*
	No remission	75	24 colonic*
Postoperative patients with CD undergoing ileocecal resection with ileocolonic anastomosis	No postoperative recurrence (Rutgeerts score i0/i1 at month 6)	36	8 neoterminal ileal**
	Postoperative recurrence (Rutgeerts score ≥ i2b at month 614)	46	24 neoterminal ileal**
	Control patients without IBD	43	12 ileal**
Multiple-affected families with IBD (minimum 3 FDRs with IBD)	Patients with IBD	48	—
	Unaffected FDRs	33	—
	Members of control families without IBD	40	—

RNAseq indicates RNA sequencing. *RNA sequencing based; **Microarray based.